Haemochromatosis is a complex inherited disorder of iron metabolism that affects a significant number of individuals worldwide. Clinicians must understand that haemochromatosis management has evolved significantly with the discovery of HFE gene variants. Excessive iron accumulation often results in serious end-organ dysfunction. Without timely intervention, patients may develop chronic liver disease, arthropathy, or severe endocrinopathies. Fortunately, early diagnosis through iron studies can facilitate prompt treatment and prevent irreversible damage.

Advanced Strategies in Haemochromatosis Management

Modern diagnostic protocols involve assessing serum transferrin saturation and ferritin levels simultaneously. For instance, a transferrin saturation level of 45% or higher typically warrants genetic testing for HFE variants like C282Y or H63D. Consequently, identifying these mutations allows for more targeted surveillance of first-degree relatives. Moreover, sex-specific differences influence the clinical phenotype, as women often present later due to natural iron loss. Therefore, physicians must maintain a high index of suspicion in patients presenting with unexplained fatigue or joint pain.

Venesection, or therapeutic phlebotomy, remains the primary therapeutic approach for iron removal. This procedure is highly effective in reducing iron stores and improving long-term survival. Additionally, clinicians should aim for a maintenance ferritin target of less than 100 µg/L. Lifestyle modifications, such as limiting alcohol and avoiding iron supplements, also play a crucial role. Furthermore, regular monitoring for complications like hepatocellular carcinoma is essential for patients with established cirrhosis. By implementing these evidence-based practices, healthcare providers can ensure optimal patient outcomes and life expectancy.

Frequently Asked Questions

What are the primary genetic markers for haemochromatosis?

The most common genetic markers are variants in the HFE gene, specifically C282Y and H63D. Homozygosity for C282Y is the leading cause of clinical iron overload in most populations.

How often should patients undergo venesection?

The frequency of venesection depends on the initial iron load and the patient's response to therapy. During the induction phase, it may occur weekly, while maintenance typically requires sessions every two to four months to keep ferritin levels within the target range.

Can diet alone manage iron overload?

While dietary changes help, they cannot replace venesection for patients with significant iron overload. However, avoiding vitamin C supplements and limiting alcohol intake are recommended to support overall management.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Fiori JG et al. Haemochromatosis - a modern clinician's guide. Intern Med J. 2026 Apr 30. doi: 10.1111/imj.70427. PMID: 42060936.

Girelli D et al. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood. 2022;139(20):3018-3029.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502.